Clinical Trials on Thoracic Tumors in Singapore

Total 346 results

National Cancer Institute (NCI)

Completed

Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in China

Lung Neoplasms

China
National Cancer Centre, Singapore
Novartis

Unknown

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour

Singapore
S*BIO

Completed

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Myelodysplastic Syndrome | Solid Tumors | Hematologic Malignancies

United States, Singapore
Debiopharm International SA

Terminated

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Solid Tumours

Korea, Republic of, United States, Taiwan, Spain, Singapore
Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors (CCGM097X2101)

Solid Tumor With p53 Wild Type Status

France, Germany, Singapore, Switzerland, United States
Prelude Therapeutics

Recruiting

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancers | SMARCA4 Gene Mutation

United States, France, Spain, Singapore, Netherlands
National Cancer Centre, Singapore

Recruiting

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer

Korea, Republic of, Taiwan, Singapore
Astellas Pharma Global Development, Inc.

Completed

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Advanced Solid Tumors

Germany, Czechia, United States, Brazil, Poland, Singapore, Thailand
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Novartis Pharmaceuticals

Terminated

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Solid Tumors

United States, Taiwan, Spain, Canada, Italy, Singapore, Japan, Hong Kong
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous NSCLC

Recurrent Non Small Cell Lung Cancer

United States, Singapore
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
Novartis Pharmaceuticals

Terminated

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Melanoma | Ovarian Neoplasms | Non-Small-Cell Lung Carcinoma | Other Solid Tumors

Spain, Germany, Singapore, Switzerland, Japan, United States
Novartis Pharmaceuticals

Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid Tumors

Korea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
Novartis Pharmaceuticals

Completed

Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function

Hepatic Impairment | Solid Tumors

Belgium, Germany, Netherlands, Italy, Singapore, United States
Hoffmann-La Roche

Completed

Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

United States, Korea, Republic of, Australia, Canada, Germany, Singapore
Array Biopharma, now a wholly owned subsidiary...

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Advanced Solid Tumors | Selected Solid Tumors

United States, Germany, Canada, Spain, Netherlands, Singapore, Switzerland
Dracen Pharmaceuticals, Inc.

Terminated

Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Advanced Solid Tumor | Non Small Cell Lung Cancer Metastatic

United States, Taiwan, Germany, Singapore, Spain
EDDC (Experimental Drug Development Centre), A*STAR...
PPD

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Solid Tumors

United States, Singapore
Novartis Pharmaceuticals

Terminated

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

Advanced Solid Tumors

Spain, Japan, Taiwan, Italy, Switzerland, Israel, United States, Singapore
GlaxoSmithKline

Completed

Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)

Singapore, Korea, Republic of
Genentech, Inc.

Active, not recruiting

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Solid Tumors

United States, Italy, Korea, Republic of, Spain, Denmark, Taiwan, Australia, France, Netherlands, United Kingdom, Singapore, Belgium, Japan, Canada
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada, Singapore, United Kingdom, Belgium
Bayer

Active, not recruiting

A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

Advanced Solid Tumors

United States, Singapore, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

France, Netherlands, Spain, Canada, Singapore, Germany, Korea, Republic of, Australia, Belgium, Switzerland, Italy, United States
National Cancer Centre, Singapore
Guardant Health AMEA, Inc.

Recruiting

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Non-small Cell Lung Cancer | ALK-Positive Lung Cancer

Korea, Republic of, Hong Kong, Malaysia, Singapore
Boehringer Ingelheim

Completed

Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, Taiwan, Singapore, Japan
The Hospital for Sick Children
Terry Fox Foundation

Active, not recruiting

Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

Retinoblastoma

Canada, Chile, India, Singapore
National Cancer Centre, Singapore
Singapore General Hospital

Recruiting

Molecular Profiling Project

Non-Small Cell Lung Cancer | Lung Cancer

Thailand, Singapore, Hong Kong, Brunei Darussalam, India, Malaysia
Novartis Pharmaceuticals

Completed

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Advanced Solid and Hematological TP53wt Tumors

France, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

Gastrointestinal Stromal Tumors

Taiwan, Japan, China, Australia, Singapore
Day One Biopharmaceuticals, Inc.
Pacific Pediatric Neuro-Oncology Consortium

Recruiting

A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)

Advanced Solid Tumor | Low-grade Glioma

United States, Israel, Korea, Republic of, Denmark, Singapore, Netherlands, Canada, Australia, Germany, Switzerland, United Kingdom
Pfizer

Completed

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Solid Tumors Harboring a BRAF V600 Mutation

United States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
BioNTech SE

Recruiting

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Solid Tumor

United States, United Kingdom, Spain, Singapore
Australasian Gastro-Intestinal Trials Group
European Organisation for Research and Treatment of Cancer - EORTC; Scandinavian...

Active, not recruiting

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)

Gastrointestinal Stromal Tumour

Singapore, Norway, Finland, Australia, Sweden, France, United Kingdom, Spain, Netherlands, Slovakia
National Cancer Institute (NCI)

Terminated

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Paraganglioma | Metastatic Adrenal Gland Pheochromocytoma | Recurrent Adrenal Gland Pheochromocytoma | Extra-Adrenal Paraganglioma

United States, Singapore, Hong Kong
Novartis Pharmaceuticals

Terminated

Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumor

Spain, Singapore, Japan, United States, Canada
Novartis Pharmaceuticals

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Advanced Solid Tumors Which Are cMET-dependent

Germany, Korea, Republic of, Belgium, Italy, Singapore, United States, Denmark, Spain, France, Canada
Merck Sharp & Dohme LLC

Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Von Hippel-Lindau Disease | Pancreatic Neuroendocrine Tumor | Pheochromocytoma/Paraganglioma | Advanced Gastrointestinal Stromal Tumor | HIF-2α Mutated Cancers

Canada, United States, Denmark, France, Germany, Hungary, Italy, Russian Federation, Spain, Sweden, Turkey, Israel, United Kingdom, Netherlands, Australia, China, Singapore, Japan
Novartis Pharmaceuticals

Completed

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Solid Tumors | Lymphomas

Spain, Canada, Singapore, Israel, Japan, United States
Pfizer

Completed

Rollover Protocol for Prior SU011248 Protocols

Solid Tumors

United States, Australia, Italy, Greece, Sweden, Switzerland, United Kingdom, Canada, Singapore, France, Netherlands
Millennium Pharmaceuticals, Inc.

Completed

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

Australia, Singapore, Netherlands
Turning Point Therapeutics, Inc.

Recruiting

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Lymphoma | Locally Advanced Solid Tumors | Metastatic Solid Tumors | Primary CNS Tumors

United States, Korea, Republic of, Spain, Singapore, Taiwan, Australia, Italy, Canada, France, Denmark, United Kingdom
National University Hospital, Singapore
AstraZeneca; Singapore Clinical Research Institute

Unknown

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (PLASMA)

Carcinoma, Non-Small-Cell Lung

Taiwan, Hong Kong, Thailand, Singapore, Korea, Republic of
Hummingbird Bioscience
Merck KGaA, Darmstadt, Germany

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Australia, Singapore
Bayer

Completed

Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (ROCOCO)

Advanced or Metastatic Solid Tumor

United States, Spain, Korea, Republic of, Belgium, Singapore, Germany
Pfizer

Completed

A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

Gastrointestinal Stromal Tumor

United States, Australia, Belgium, Italy, Singapore, Spain, Switzerland, United Kingdom, Canada, France, Netherlands
Cancer Therapeutics Research Group
National Cancer Institute (NCI)

Completed

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Australia, Singapore, Hong Kong, Korea, Republic of
Hoffmann-La Roche

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Endocrine System Diseases | Gastrointestinal Neoplasms | Neoplasms, Germ Cell and Embryonal | Head and Neck Neoplasms | Carcinoma, Non-Small-Cell Lung | Respiratory Tract... and other conditions

France, Spain, United States, Korea, Republic of, United Kingdom, Taiwan, China, Belgium, Singapore, Netherlands, Germany, Italy, Hong Kong
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong

Clinical Trials on Thoracic Tumors in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations